

Genovis Q3 2024 - Beat across the board

Redeye provides an updated view on Genovis following a Q3 report that surpassed our estimates across the board. We have made slight adjustments to our model and largely reaffirm our fair value range, indicating a favorable risk/reward balance in the share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Genovis Q3 2024 - Beat across the board